Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Stimulant Abuse (September/October) | 2014

View Archived Issues

Alcohol Responsible for 10% of Adult Deaths in US

September 1, 2014

A new report from the Centers for Disease Control and Prevention (CDC) says that in adults ages 20 to 64, one in 10 deaths are the result of excessive drinking. Read More

Cognitive Enhancers: Smart Drugs or Bad Idea?

September 1, 2014

Today’s conversation about “smart drugs” is fundamentally different and refers to the use of medications by people without psychiatric disorders who seek a boost or cognitive edge. Read More

Deconstructing Red Bull

September 1, 2014

Americans guzzled a mind-blowing 3.5 billion energy drinks in 2013, with sales totaling $8.7 billion. But what, exactly, are energy drinks? Do they actually give you energy? And are they safe? Read More

Malingered ADHD

September 1, 2014

Get insight into the problem of malingering—in other words faking—ADHD symptoms by patients who may want to receive academic accommodations or obtain prescription stimulants, in an interview with researcher Mandi Musso, PhD. Read More

Substance Abuse Treatment for Individuals with Traumatic Brain Injury

September 1, 2014

Learn some of the key best practices that can help you work with patients in substance abuse treatment who also have a traumatic brain injury, in an interview with Duane Reynolds, LSW, LADC, associate director of the Vinland National Center in Minnesota. Read More

Evaluating and Treating ADHD Symptoms in Patients with Addiction

September 1, 2014

Find out more about how you can evaluate and treat ADHD symptoms in patients with addiction, in an interview with clinical neuropsychologist Christopher B. Mertz. Read More

Buprenorphine Reduces Total Cost of Care

September 1, 2014

Buprenorphine (Suboxone and others) is an effective medication for treating patients with opioid addiction. Research has shown that it works better than standard psychosocial or “abstinence-based” treatments. But is the cost of the drug worth the extra therapeutic benefit? Read More

Two Old Drugs Made New

September 1, 2014

Naltrexone, which first hit the US market in 1984 as a treatment for alcohol dependence, continues to find new uses. Its latest incarnation, Contrave, was just approved by the Food and Drug Administration (FDA) in September as a weight loss medication. Read More